WST 1

Drug Profile

WST 1

Alternative Names: Topical pirenzepine - WinSanTor; WST-1; WST01; WST1/analgesic

Latest Information Update: 26 Apr 2017

Price : $50

At a glance

  • Originator University of Manitoba
  • Developer WinSanTor
  • Class Antidementias; Antiulcers; Benzodiazepinones; Gastric antisecretories; Small molecules
  • Mechanism of Action Muscarinic M1 receptor antagonists; Sensory receptor cell modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Diabetic neuropathies
  • Research Neuropathic pain

Most Recent Events

  • 26 Apr 2017 WinSanTor plans a phase I trial in Healthy volunteers in Australia (ACTRN12617000535370p)
  • 10 Aug 2016 WST 1 is available for licensing - http://winsantor.com/pages/contact-us-2/
  • 10 Aug 2016 Early research in Neuropathic pain in USA (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top